Trial Profile
A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Therapeutic Use
- 29 Nov 2018 New trial record